

05-16-06

Itm



CASE ON/4-30811A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 540157243US
Express Mail Label Number

May 15, 2006
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT APPLICATION OF: Matthews, et al.

Art Unit: 1614

Examiner: B.Y.S. Kwon

APPLICATION NO: 09/930,335 ✓

FILED: August 15, 2001

U.S. APPLICATION NO: 09/930,335

FOR: SPONTANEOUSLY DISPERSIBLE N-BENZOYL STAUROSPORINE
COMPOSITIONS

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Kristin Konzak
Attorney for Applicant
Reg. No. 44,848

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3216

Date: 15 May 06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

FILING DATE

Group
1614**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,735,939	4/5/88	McCoy et al.	514	211	
	AB	4,963,367	10/16/90	Ecanow	424	485	
	AC	5,093,330	3/3/92	Caravatti et al.	514	211	
	AD	5,444,041	8/22/95	Owen et al.	514	356	
	AE	5,599,808	2/4/97	Goldstein et al.	514	211	
	AF	5,639,474	6/17/97	Woo	427	465	
	AG	5,658,898	8/19/97	Weder et al.	514	211	
	AH	5,707,648	1/13/98	Yiv	424	450	
	AI	5,726,164	3/10/98	Weder et al.	514	80	
	AJ	5,736,542	4/7/98	Henry et al.	514	211	
	AK	5,932,243	8/3/99	Fricker et al.	424	450	
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	EP 0 657 164 A	6/14/05	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 98 33512 A	8/6/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 0 733 358 A2	9/25/96	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AP	EP 0 711 556 A1	5/15/06	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	DE 44 18 115 A1	5/24/94	Germany			<input type="checkbox"/>	<input checked="" type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Alkan et al. "Effects of a New Protein Kinase C Inhibitor CGP 41251 on T Cell Functions: Inhibition of Activation, Growth, and Target Cell Killing," Cellular Immunology, Vol. 150, pp. 137-148 (1993)
	AS	Andrejauskas-Buchdunger et al. "Differential Inhibition of the Epidermal Growth Factor-, Platelet-derived Growth Factor-, and Protein Kinase C-mediated Signal Transduction Pathways by the Staurosporine Derivative CGP 41251," Cancer Research, Vol. 52, pp.
	AT	Begemann, Martin et al. "Inhibition of the Growth of Glioblastomas by CGP 41251, an Inhibitor of Protein Kinase C, and by a Phorbol Ester Tumor Promoter," Clinical Cancer Research, Vol. 2, pp. 1017-1030 (1996)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30811A
APPLICATION NO.
09/930,335
APPLICANT

FILING DATE

Group
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	BM	GB 2 308 545 A	7/2/97	Great Britain			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO 95/14037	5/26/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO 98/15255	4/16/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BP	WO 98/18321	5/7/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BQ	WO 98/13032	4/2/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BR	WO 98/30204	7/16/98	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Begemann, Martin. "Treatment of Human Glioblastoma Cells with the Staurosporine Derivative CGP 41251 Inhibits CDC2 and CDK2 Kinase Activity and Increase Radiation Sensitivity," Anticancer Research. Vol 18. pp. 2275-2282 (1998)
	BS	Blobe, Gerard, et al. "Selective Regulation of Expression of Protein Kinase C (PKC) Isoenzymes in Multidrug-resistant MCF-7 Cells," Journal of Biological Chemistry, Vol. 268, No. 1, pp. 658-664 (1993)
	BT	Caravatti, et al. "Inhibitory Activity and Selectivity of Staurosporine Derivatives towards Protein Kinase C," Bioorganic & Medicinal Chemistry Letters, Vol. 4, No. 3. pp. 399-404. (1994)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30811A
APPLICATION NO.
09/930,335
APPLICANT

FILING DATE

Group
1614EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Chung, Denise et al. "Evidence that the ras oncogene-enclosed p21 protein induces oocyte maturation via activation of protein kinase C," Proc. Natl. Acad. Sci. USA, Vol 89, pp. 1993-1996. (1992)
DB	Dietel, Manfred. "Second International Symposium on Cytostatic Drug Resistance," Cancer Research, Vol. 53, pp.2683-2688 (1993)
DC	Erikson, Raymond L. "Structure, Expression, and Regulation of Protein Kinases Involved in the Phosphorylation of Ribosomal Protein S6," Journal of Biological Chemistry, Vol. 266, No. 10. pp. 6007-6010 (1991)
DD	Fuse, E. et al. "Unpredicated Clinical Pharmacology of UCN-01 Caused by Specific Binding to Human alpha1-Acid Glycoprotein," Cancer Research, Vol. 58, pp. 3248-3253, (1998)
DE	Gottesman, Michael M. "How Cancer Cells Evade Chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture," Cancer Research 53, pp. 747-754 (1993)
DF	Hill, D.L, et al. "Binding of UCN-01 to Plasma Proteins of Humans, Rats and Dogs," Proceeding of the Amer. Assoc. for Cancer Research, Vol. 39, p. 364 (1998)
DG	Ikegami Y. et al. "Effects of the New Selective Protein Kinase C Inhibitor 4'-N-Benzoyl Staurosporine on Cell Cycle Distribution and Growth Inhibition in Human Small Lung Cancer Cells", Jpn. J. Pharmacol. Vol. 70, pp. 65-72 (1996)
DH	Ikegami, Yuri et al. "Antitumor Effect of CGP41251, a New Selective Protein Kinase C Inhibitor, on Human Non-Small Cell Lung Cancer Cells," Jpn. J. Pharmacol., Vol. 70. pp. 65-72 (1996)
DI	Killion J.J. et al. "The Antitumor Activity of Doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of synthetic staurosporine analogue," Oncology Research, Vol. 7, No. 9, pp. 453-459 (1995)
DJ	Ludescher Ch. et al. "Decreased Potency of MDR-modulators under serum conditions determined by a functional assay," Brit. J. of Haematology, Vol. 91, pp. 652-657 (1995)
DK	Mack, P.C. et al. "7-hydroxystaurosporine (UCN-01) plus cisplatin (CDPP): molecular mechanisms of dose-,time- and sequence-dependent potentiation in non-small cell lung carcinoma (NSCLC)," Clinical Pharmacology, Proceeding of Asco, Vol. 16. pp. 212a. (1)
DL	Marte, B.M. et al. "Protein Kinase C and Mammary Cell Differentiation: Involvement of Protein Kinase C alpha in the Induction of Beta-Casein Expression," Cell Growth & Differentiation, Vol. 5, pp. 239-247 (1994)
DM	Matter A., et al. "Pharmacological Approach to growth regulation of breast cancer cells", pp. 227-241
DN	Meggio, Flavio, et al. "Different susceptibility of protein kinases to staurosporine inhibition," Eur. J. Biochem, Vol. 234, pp. 317-322. (1995)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

4-30811A

APPLICATION NO.

09/930,335

APPLICANT

FILING DATE

Group
1614EXAMINER
INITIAL**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Meyer, Th., et al. "A Derivative of Staurosporine (CGP 41 251) Shows Selectivity For Protein Kinase C Inhibition and In Vitro Anti-proliferative as well as In Vivo Anti-tumor Activity," Int. J. Cancer, vol. 43, pp. 851-856 (1989)
	DB	Miyamoto, Ken-ichi. "Inhibition of Multidrug Resistance by a New Staurosporine Derivative, NA-382, in Vitro and in Vivo," Cancer Research. Vol. 53. pp. 1555-1559. (April 1, 1993)
	DC	Pastan et al. "Multidrug Resistance," Annu. Rev. Med., Vol. 42, pp. 277-86 (1991)
	DD	Sampson, K.E. et al. "Staurosporine reduces P-glycoprotein expression and modulates multidrug resistance," Cancer Letters, Vol. 68, pp. 7-14 (1993)
	DE	Sato, Wakao et al. "Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells," Biochemical and Biophysical Research Communications, Vol. 173, No. 3 (1990)
	DF	Sedlak, J. et al. "Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines," Anti-Cancer Drugs Vol. 6, pp. 70-76 (1995)
	DG	Simon, Sanford et al. "Cell biological mechanisms of multidrug resistance in tumors," Proc. Natl. Acad. Sci, USA, Vol. 91, pp. 3497-3504 (1994)
	DH	Susa, Mira et al. "Inhibition or Down-regulation of Protein Kinase C Attenuates Late Phase p70s6k Activation Induced by Epidermal Growth Factor but Not by Platelet-derived Growth Factor or Insulin," Journal of Biological Chemistry, Vol. 267, No. 10. pp.
	DI	Utz, I. et al. "The Protein Kinase C Inhibitor CGP 41251, A Staurosporine Derivative with Antitumor Activity, Reverses Multidrug Resistance," Int. J. Cancer, Vol. 57, pp. 104-110 (1994)
	DJ	Utz, Irene. "Reversal of Multidrug Resistance by the Staurosporine Derivatives CGP 41251 and CGP 42700," Int. J. Cancer. Vol. 77 pp.64-69 (1998)
	DK	Van Kalken, et al. "Multidrug Resistance form the Clinical Point of View" Eur. J Cancer, Vol. 27, No. 11. pp. 1481-1486. (1991)
	DL	Schwarz, et al. "Effect on the partition equilibrium of various drugs by the formation of mixed bile salt/phosphatidylcholine/fatty acid micelles A characterization by micellar affinity capillary electrophoresis Part IV,": Journal of Chromatography A, Vol. 809 pp. 219-229 (1998)
	DM	Borkovec, Michal. "Phenomenological Theories of Globular Microemulsion," Advances in Colloid and Interface Science. Vol. 37, pp. 195-217 (1992)
	DN	Beltran, Pedro et al. "Chemosensitization of Cancer Cells by the Staurosporine Derivative CGP 41251 in Association with Decreased P-Glycoprotein Phosphorylation," Biochemical Pharmacology Vol 53 pp. 245-247 (1997)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.